Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection

Next Previous
Search
Trial Profile

A Phase I Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RO-7565020 (Primary) ; RO-7565020 (Primary) ; Entecavir; Tenofovir alafenamide; Tenofovir disoproxil fumarate
  • Indications Hepatitis B
  • Focus Adverse reactions; First in man
  • Sponsors Roche

Most Recent Events

  • 07 Jan 2025 Status changed from recruiting to discontinued. (Reason the study was stopped: The Sponsor decided to discontinue the development of RO7565020 and as a result the BP44118 study was terminated).
  • 08 Jul 2024 Planned End Date changed from 1 Feb 2027 to 13 May 2026.
  • 08 Jul 2024 Planned primary completion date changed from 1 Feb 2027 to 13 May 2026.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top